Gail Farfel is a biotech executive and board member with over 25 years of experience in developing treatments for central nervous system disorders. With a PhD in neuropsychopharmacology from the University of Chicago, she has a proven track record in clinical development and regulatory strategy, particularly in rare neurological and neurodegenerative diseases.
Outside of her executive roles, Gail is deeply committed to patient advocacy for those affected by rare epilepsies, serving as a director for the Dravet Syndrome Foundation. In her free time, she enjoys hiking, skiing, and training her rescue dog, Sadie.
She was instrumental in the development and global regulatory approval of FINTEPLA, a key treatment for seizures associated with Dravet and Lennox-Gastaut syndromes.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.